A group of medical experts has called for biomarkers to play a more central role in clinical practice.
According to a report by MedPage Today, a group led by Dr Bruno Dubois of Paris' Salpetriere Hospital, wants to see clinicians using biomarker data to aid their diagnosis of patients suffering from Alzheimer's disease, or of patients with conditions that may lead on to Alzheimer's disease.
The online medical publication reported that 24 members of the International Working Group for New Research Criteria for the Diagnosis of Alzheimer's Disease want to see biomarkers in cerebrospinal fluid, or data gathered from the use of amyloid-specific tracers during MRI or PET scans, used as part of clinicians' diagnosis of Alzheimer's disease.
Their call for biomarkers to take a more prominent role in the diagnosis of Alzheimer's disease is an important step, and one that shows how far biomarkers have come.
More is known about biomarkers than ever before and they playing an increasingly important part in helping researchers to gather data and conduct tests into helping to diagnose diseases such as Alzheimer's at an early stage.
While there are experts who believe it is too early for biomarkers to be used by clinicians on a routine basis, it is vital that they continue to be integrated into the research process so new data and evidence can be obtained.
The group of experts led by Dr Dubois believe that in this evolving field, the use of biomarkers might reach regulatory approval in the foreseeable future.
If biomarkers are to receive regulatory status then it is extremely important that research continues.
There are thankfully organisations that believe strongly in the value of biomarker research and how it can play a vital part in studies.
The use of cancer biomarkers is one area of research that is undeniably important and work is underway all over the world to increase knowledge and find ways of using biomarkers to spot diseases at their earliest stage.
Unfortunately finances are limited and there is much work to do, but the continued use of biomarkers by researchers and the commitment of a number of companies to continue their efforts to gather data and increase understanding is all helping.
According to a report by MedPage Today, a group led by Dr Bruno Dubois of Paris' Salpetriere Hospital, wants to see clinicians using biomarker data to aid their diagnosis of patients suffering from Alzheimer's disease, or of patients with conditions that may lead on to Alzheimer's disease.
The online medical publication reported that 24 members of the International Working Group for New Research Criteria for the Diagnosis of Alzheimer's Disease want to see biomarkers in cerebrospinal fluid, or data gathered from the use of amyloid-specific tracers during MRI or PET scans, used as part of clinicians' diagnosis of Alzheimer's disease.
Their call for biomarkers to take a more prominent role in the diagnosis of Alzheimer's disease is an important step, and one that shows how far biomarkers have come.
More is known about biomarkers than ever before and they playing an increasingly important part in helping researchers to gather data and conduct tests into helping to diagnose diseases such as Alzheimer's at an early stage.
While there are experts who believe it is too early for biomarkers to be used by clinicians on a routine basis, it is vital that they continue to be integrated into the research process so new data and evidence can be obtained.
The group of experts led by Dr Dubois believe that in this evolving field, the use of biomarkers might reach regulatory approval in the foreseeable future.
If biomarkers are to receive regulatory status then it is extremely important that research continues.
There are thankfully organisations that believe strongly in the value of biomarker research and how it can play a vital part in studies.
The use of cancer biomarkers is one area of research that is undeniably important and work is underway all over the world to increase knowledge and find ways of using biomarkers to spot diseases at their earliest stage.
Unfortunately finances are limited and there is much work to do, but the continued use of biomarkers by researchers and the commitment of a number of companies to continue their efforts to gather data and increase understanding is all helping.
SHARE
